美国 · 平台与数据 · Seeking Alpha
Ideaya picks cancer drug candidate, targets human trial application in 2027

详细摘要
Ideaya Biosciences selects IDE101, a preclinical drug candidate for cancers lacking CDKN2A, and aims to seek U.S.
Ideaya Biosciences (IDYA) on Sunday said it selected IDE101 as a drug candidate for further development to treat cancers lacking CDKN2A, a gene that normally helps prevent uncontrolled cell growth. The company aims to seek U.S. regulatory permission to begin human testing
文章开头,摘自Seeking Alpha。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (seekingalpha.com)




